K Jung1, M Lein, C Laube, R Lichtinghagen. 1. Department of Urology, University Hospital Charité, Humboldt University Berlin, Schumannstrasse 20/21, D-10098 Berlin, Germany. klaus.jung@charite.de
Abstract
BACKGROUND: Matrix metalloproteinases (MMP) in blood are promising new diagnostic tools. It was shown that the blood sampling process resulted in different blood concentrations of MMPs. To clarify whether the sampling process also influences the diagnostic validity of MMPs, MMP-9 measurements were performed in plasma and serum samples of patients with prostate carcinoma and renal cell cancer. METHODS: MMP-9 ELISAs were performed in samples of heparin plasma and serum collected in blood tubes with and without clot accelerator. Measurements were undertaken in 78 healthy persons, 33 patients with prostate carcinoma and 33 patients with renal cell carcinoma. RESULTS: MMP-9 showed higher concentrations in serum samples than in heparin plasma and was about threefold higher in serum samples collected in tubes with clot activator than in native serum samples. Both patient groups had lower MMP-9 concentrations in serum, whereas in plasma, patients with renal cell carcinoma had higher, but patients with prostate cancer unchanged MMP-9 concentrations. 13 of 33 patients with renal cell carcinoma had increased MMP-9 plasma values but no patient had increased serum concentrations. CONCLUSIONS: To optimise the diagnostic validity of the MMP-9 in blood, measurements should be performed in heparin plasma but not in serum.
BACKGROUND: Matrix metalloproteinases (MMP) in blood are promising new diagnostic tools. It was shown that the blood sampling process resulted in different blood concentrations of MMPs. To clarify whether the sampling process also influences the diagnostic validity of MMPs, MMP-9 measurements were performed in plasma and serum samples of patients with prostate carcinoma and renal cell cancer. METHODS:MMP-9 ELISAs were performed in samples of heparin plasma and serum collected in blood tubes with and without clot accelerator. Measurements were undertaken in 78 healthy persons, 33 patients with prostate carcinoma and 33 patients with renal cell carcinoma. RESULTS:MMP-9 showed higher concentrations in serum samples than in heparin plasma and was about threefold higher in serum samples collected in tubes with clot activator than in native serum samples. Both patient groups had lower MMP-9 concentrations in serum, whereas in plasma, patients with renal cell carcinoma had higher, but patients with prostate cancer unchanged MMP-9 concentrations. 13 of 33 patients with renal cell carcinoma had increased MMP-9 plasma values but no patient had increased serum concentrations. CONCLUSIONS: To optimise the diagnostic validity of the MMP-9 in blood, measurements should be performed in heparin plasma but not in serum.
Authors: J Decock; W Hendrickx; H Wildiers; M R Christiaens; P Neven; M Drijkoningen; R Paridaens Journal: Clin Exp Metastasis Date: 2005 Impact factor: 5.150
Authors: Pınar Yıldız Gülhan; Mehmet Savaş Ekici; Mehmet Niyaz; Muhammet Gülhan; Mustafa Emre Erçin; Aydanur Ekici; Nurkan Aksoy Journal: Turk Thorac J Date: 2020-01-01
Authors: Fabio M Iwamoto; Andreas F Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Lisa M Deangelis; Eric C Holland; Adília Hormigo Journal: J Neurooncol Date: 2011-06-28 Impact factor: 4.130
Authors: Andreas F Hottinger; Fabio M Iwamoto; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Joseph Park; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Eric C Holland; Lisa M DeAngelis; Adília Hormigo Journal: Ann Neurol Date: 2011-03-09 Impact factor: 10.422
Authors: Rosane M B Teles; Rose B Teles; Thais P Amadeu; Danielle F Moura; Leila Mendonça-Lima; Helen Ferreira; Italo M C F Santos; José A C Nery; Euzenir N Sarno; Elizabeth P Sampaio Journal: Infect Immun Date: 2009-12-14 Impact factor: 3.441